Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study

NCT04055792 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04055792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2019
Completion date
May 1, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive disease small cell lung cancer